Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAXNASDAQ:GNFTNASDAQ:IMNMNASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$14.54-7.0%$12.79$8.91▼$28.09$792.76MN/A475,484 shs593,665 shsGNFTGenfit$3.64-0.8%$3.50$2.55▼$6.42$181.99M1.2214,747 shs3,067 shsIMNMImmunome$8.40-1.4%$8.00$5.15▼$16.81$730.39M2.05907,306 shs1.64 million shsPRAXPraxis Precision Medicines$36.00$40.27$26.70▼$91.83$725.87M2.66380,904 shs300,541 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics0.00%+19.57%+8.51%+25.34%+1,453,999,900.00%GNFTGenfit0.00%+4.45%+2.54%+2.39%+5.66%IMNMImmunome0.00%+6.19%+15.38%-15.58%-41.14%PRAXPraxis Precision Medicines0.00%+6.54%-7.34%-53.31%-29.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGNFTGenfit1.4325 of 5 stars3.52.00.00.02.00.00.0IMNMImmunome2.5882 of 5 stars4.50.00.00.03.22.50.0PRAXPraxis Precision Medicines3.0981 of 5 stars4.44.00.00.02.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 2.89Moderate Buy$32.43123.04% UpsideGNFTGenfit 3.00Buy$13.00257.14% UpsideIMNMImmunome 3.00Buy$25.14199.32% UpsidePRAXPraxis Precision Medicines 2.78Moderate Buy$123.33242.59% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, PRAX, IMNM, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight$8.004/8/2025PRAXPraxis Precision MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.00 ➝ $85.004/7/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $44.004/2/2025IMNMImmunomeLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.003/27/2025BCAXBicara TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$48.003/27/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.003/20/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $33.003/20/2025IMNMImmunomeStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/20/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$35.00 ➝ $25.003/13/2025BCAXBicara TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.01 ➝ $13.013/11/2025IMNMImmunomeLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AGNFTGenfit$76.06M2.39N/AN/A$1.48 per share2.46IMNMImmunome$9.04M80.79N/AN/A$2.77 per share3.03PRAXPraxis Precision Medicines$8.55M84.87N/AN/A$7.92 per share4.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/A6/26/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/AIMNMImmunome-$106.81M-$5.17N/AN/AN/A-3,014.59%-48.63%-41.62%5/13/2025 (Estimated)PRAXPraxis Precision Medicines-$123.28M-$10.27N/AN/AN/A-9,409.22%-54.86%-50.52%5/12/2025 (Estimated)Latest GNFT, PRAX, IMNM, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMNMImmunome-$0.67N/AN/AN/A$0.46 millionN/A5/12/2025Q1 2025PRAXPraxis Precision Medicines-$3.20N/AN/AN/A$0.18 millionN/A3/27/2025Q4 2024BCAXBicara Therapeutics-$0.31-$0.39-$0.08-$0.39N/AN/A3/19/2025Q4 2024IMNMImmunome-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million2/28/2025Q4 2024PRAXPraxis Precision Medicines-$2.76-$2.94-$0.18-$2.94$0.36 million$7.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/AN/AN/AGNFTGenfit0.613.743.74IMNMImmunomeN/A6.176.17PRAXPraxis Precision MedicinesN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/AGNFTGenfit2.24%IMNMImmunome44.58%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipBCAXBicara TherapeuticsN/AGNFTGenfit4.20%IMNMImmunome8.60%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.52 millionN/AN/AGNFTGenfit12050.00 million47.90 millionNot OptionableIMNMImmunome4086.95 million72.92 millionOptionablePRAXPraxis Precision Medicines11020.16 million18.14 millionOptionableGNFT, PRAX, IMNM, and BCAX HeadlinesRecent News About These CompaniesJump Financial LLC Takes $861,000 Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 24 at 4:23 AM | marketbeat.comPraxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | BenzingaApril 21, 2025 | benzinga.comPraxis Precision Medicines (NASDAQ:PRAX) vs. Dr. Reddy's Laboratories (NYSE:RDY) Head-To-Head SurveyApril 21, 2025 | americanbankingnews.comComparing Praxis Precision Medicines (NASDAQ:PRAX) & ABIVAX Société Anonyme (NASDAQ:ABVX)April 20, 2025 | americanbankingnews.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 6.1% - Should You Buy?April 19, 2025 | marketbeat.comWalleye Capital LLC Acquires 34,000 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 18, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $123.33 Average Price Target from BrokeragesApril 17, 2025 | americanbankingnews.comAlliancebernstein L.P. Buys 60,587 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 15, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 15, 2025 | marketbeat.comWellington Management Group LLP Sells 155,973 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 13, 2025 | marketbeat.comVanguard Group Inc. Buys 24,645 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 12, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 6.6% - Time to Sell?April 10, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Receives Buy Rating from Needham & Company LLCApril 10, 2025 | marketbeat.comNorges Bank Purchases New Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 10, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Hits New 12-Month Low - Should You Sell?April 9, 2025 | marketbeat.comPraxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesApril 8, 2025 | globenewswire.comFranklin Resources Inc. Sells 55,398 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)April 7, 2025 | marketbeat.com45,427 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by Pictet Asset Management Holding SAApril 6, 2025 | marketbeat.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3, 2025 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | gurufocus.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNFT, PRAX, IMNM, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$14.54 -1.09 (-6.97%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$14.52 -0.02 (-0.14%) As of 04/25/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Genfit NASDAQ:GNFT$3.68 +0.01 (+0.30%) As of 04/25/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Immunome NASDAQ:IMNM$8.40 -0.12 (-1.41%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$8.52 +0.12 (+1.43%) As of 04/25/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Praxis Precision Medicines NASDAQ:PRAX$36.00 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$35.76 -0.24 (-0.68%) As of 04/25/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
